Results 221 to 230 of about 9,217,738 (367)

Endothelial derived microvesicles modulate cerebrovascular and brain aging via MiR‐17‐5p and the biomarker potential in vascular aging

open access: yesInterdisciplinary Medicine, EarlyView.
Y.EMVs released from young endothelial cells (ECs) prevented vascular aging by ameliorating ECs senescence and dysfunction via regulating miR‐17‐5p, and subsequently inhibited brain aging. O.EMVs released from the senescent ECs played the opposite roles, accompanied with a significant increase of EMVs level and downregulation of miR‐17‐5p encapsulated ...
Huiting Zhang   +9 more
wiley   +1 more source

Magnetic Vestibular Stimulation (MVS) As a Technique for Understanding the Normal and Diseased Labyrinth [PDF]

open access: gold, 2017
Bryan K. Ward   +5 more
openalex   +1 more source

Perinatal Exposure to the Neonicotinoid Thiacloprid Impacts Transcription of Neuroplasticity and Neuroendocrine Markers in Mice but Not in the Zebrafish Model

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT Neonicotinoids are widely used insecticides in agriculture, aquaculture, pet care, and urban pest control. Initially developed to selectively target the insect cholinergic system, their extensive use has raised concerns about adverse effects on nontarget vertebrates.
Kirthana Kunikullaya U   +6 more
wiley   +1 more source

Bifenthrin Under Scrutiny: Revisiting Toxicological Evidence Amid Regulatory Gaps

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT Despite growing health concerns, bifenthrin (BF) remains widely used for controlling agricultural and residential pests. However, different perspectives on its toxicological profile and regulatory framework warrant a revisit and update on BF regulation towards a robust risk‐safety assessment.
Caroline V. L. Moreira   +10 more
wiley   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo   +11 more
wiley   +1 more source

Obeticholic acid prevents cyclophosphamide-induced placental injury via SIRT1 and TLR4/NF-κB pathways. [PDF]

open access: yesBMC Pharmacol Toxicol
Abdelzaher WY   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy